We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PetMed Remains Strong on New Order & Reorder Sales Gain
Read MoreHide Full Article
On Jun 13, 2016, we issued an updated research report on PetMed Express (PETS - Free Report) . This nationwide pet pharmacy presently carries a Zacks Rank #2 (Buy).
PetMed exhibited better-than-expected fourth-quarter fiscal 2016 performance, exceeding the Zacks Consensus Estimate on both lines. After several quarters of drag in new order sales, we are impressed with PetMed’s improved performance over the last two quarters.
In the fiscal fourth quarter, new order sales increased 24% to $9.4 million. In addition, reorder sales continued to show consistent growth, witnessing an 8.4% rise in the quarter to $46 million.
Further, average order size improved to $83 from $81 in the year-ago period on the back of a change in product mix to higher priced items and increased doses. The company is also working on issues like limited consumer spending and a change in product mix to lower priced items, mainly generics. The company is also asking veterinarians to prescribe more of their brands.
Although we are encouraged by PetMed’s efforts to revive the top line, barring the last two quarters, new order sales have been persistently sluggish over the last few quarters, hit by a reduction in advertising. Although the company is optimistic about the latest increase, the primary reason behind this is the unusually warm climate experienced last December compared to other years, which boosted sales. Hence, sustainability of this growth remains a concern.
Meanwhile, the company continues to face pressure in the competitive and fragmented pet medications market.
Key Picks from the Sector
Medical stocks such as ICU Medical, Inc. (ICUI - Free Report) , LeMaitre Vascular, Inc. (LMAT - Free Report) and NuVasive, Inc. , all with a Zacks Rank #2, are expected to do well over the short term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
PetMed Remains Strong on New Order & Reorder Sales Gain
On Jun 13, 2016, we issued an updated research report on PetMed Express (PETS - Free Report) . This nationwide pet pharmacy presently carries a Zacks Rank #2 (Buy).
PetMed exhibited better-than-expected fourth-quarter fiscal 2016 performance, exceeding the Zacks Consensus Estimate on both lines. After several quarters of drag in new order sales, we are impressed with PetMed’s improved performance over the last two quarters.
In the fiscal fourth quarter, new order sales increased 24% to $9.4 million. In addition, reorder sales continued to show consistent growth, witnessing an 8.4% rise in the quarter to $46 million.
Further, average order size improved to $83 from $81 in the year-ago period on the back of a change in product mix to higher priced items and increased doses. The company is also working on issues like limited consumer spending and a change in product mix to lower priced items, mainly generics. The company is also asking veterinarians to prescribe more of their brands.
Although we are encouraged by PetMed’s efforts to revive the top line, barring the last two quarters, new order sales have been persistently sluggish over the last few quarters, hit by a reduction in advertising. Although the company is optimistic about the latest increase, the primary reason behind this is the unusually warm climate experienced last December compared to other years, which boosted sales. Hence, sustainability of this growth remains a concern.
Meanwhile, the company continues to face pressure in the competitive and fragmented pet medications market.
Key Picks from the Sector
Medical stocks such as ICU Medical, Inc. (ICUI - Free Report) , LeMaitre Vascular, Inc. (LMAT - Free Report) and NuVasive, Inc. , all with a Zacks Rank #2, are expected to do well over the short term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>